Rhodanine-based Compounds Inhibit Tau Protein Aggregation

In several bioassays, inhibition of Tau protein accumulation shows that the formulation additives do not reduce drug efficacy and activity.

The drug-specific formulation additives offer access to next generation precision additives. The design of tailored peptide-polymer conjugates help in rendering problematic small organic water-soluble drugs and improves bio-availability. //

The method can be applied to a large spectrum of entities of fluorescent or non-fluorescent drugs. Herein we report the solubilization of two poorly water-soluble, potential anti-Alzheimer disease (AD) drugs based on the rhodanine core.

Tau Protein May Be The Leading Culprit in Alzheimer's Disease
New molecular imaging research is revealing how tau, rather than amyloid-deposition, may be more directly instigating neuronal dysfunction of Alzheimer's disease.

‘The drug release from the peptide-polymer conjugates is feasible, which improves cell viability and reduces apoptosis.’

The compounds showed inhibitory activity to prevent the aggregation of Tau proteins into paired helical filaments (PHFs) and neurofibrillary tangles (NFTs), both of which are associated with AD pathogenesis.

Using a fluorescence microscopy-based screening procedure, peptide sequences with high drug binding capacity are identified from large peptide libraries.

The synthesis of corresponding peptide-poly(ethylene glycol) (peptide-PEG) conjugates leads to precision formulation additives for the potential anti-AD drugs. Whereas the PEG-blocks of the conjugates provide water solubility and drug shielding, the drug specific hosting is dominated by the peptide-segments, binding the drug in a non-covalent manner and thus bypassing the requirements of additional drug approval procedures.

Shedding New Light on the Pathological Processes That Involve Tau Proteins
New light on the pathological processes that involve Tau proteins has been shed by researchers.

Application in several bioassays of inhibition of Tau protein aggregation indicated that the formulation additives do not reduce drug efficacy and activity.

The drug formulations showed a reduction of the fibril formation of the tested Tau construct comparable to the drug alone dissolved in DMSO. Thus, drug release from the conjugates is feasible.

Tau Protein Phosphorylation in Rats Subjected to Cerebral Ischemia-reperfusion Injury
Hyperphosphorylation of the microtu-bule-associated protein tau induced by transient brain ischemia, shows a study.

The activities of the compound-complexes in in vitro experiments on Tau4RDΔK280-expressing N2a cells were significantly enhanced, resulting in improved cell viability and reduced apoptosis, which correlates with a lower ratio of insoluble to soluble Tau aggregates.

The precision formulation additives offer opportunities for early stage drug structure or lead compound testing in DMSO free systems. This is important as DMSO is currently believed to affect relevant protein functions and might influence cell studies.

Tau Protein Damages the Brain in Alzheimer�s Patients and Could Make Them Wander
Accumulation of tau protein in the grid cells of the brain of Alzheimer’s patients could lead to damage and result in wandering and cognitive decline.

Source-Eurekalert